-+ 0.00%
-+ 0.00%
-+ 0.00%

FibroBiologics Issued New U.S. Patent Entitled Fibroblast Cell Therapy for Treatment of Osteoporosis

Benzinga·03/02/2026 13:37:21
Listen to the news

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled "Fibroblast Cell Therapy for Treatment of Osteoporosis."